vs

Side-by-side financial comparison of Tennessee Valley Authority (TVE) and Vertex Pharmaceuticals (VRTX). Click either name above to swap in a different company.

Vertex Pharmaceuticals is the larger business by last-quarter revenue ($3.2B vs $3.0B, roughly 1.0× Tennessee Valley Authority). Vertex Pharmaceuticals runs the higher net margin — 37.3% vs 8.7%, a 28.6% gap on every dollar of revenue. On growth, Vertex Pharmaceuticals posted the faster year-over-year revenue change (9.5% vs 4.4%). Vertex Pharmaceuticals produced more free cash flow last quarter ($348.6M vs $-814.0M). Over the past eight quarters, Vertex Pharmaceuticals's revenue compounded faster (8.9% CAGR vs -1.7%).

The Tennessee Valley Authority (TVA) is a federally-owned electric utility corporation in the United States. TVA's service area covers all of Tennessee, portions of Alabama, Mississippi, and Kentucky, and small areas of Georgia, North Carolina, and Virginia. While owned by the federal government, TVA receives no taxpayer funding and operates similarly to a private for-profit company. It is headquartered in Knoxville, Tennessee, and is the sixth-largest power supplier and largest public utilit...

Vertex Pharmaceuticals Incorporated is an American biopharmaceutical company based in Boston, Massachusetts. It was one of the first biotech firms to use an explicit strategy of rational drug design rather than combinatorial chemistry. It maintains headquarters in Boston, Massachusetts, and three research facilities, in San Diego, California, and Milton Park, Oxfordshire, England.

TVE vs VRTX — Head-to-Head

Bigger by revenue
VRTX
VRTX
1.0× larger
VRTX
$3.2B
$3.0B
TVE
Growing faster (revenue YoY)
VRTX
VRTX
+5.1% gap
VRTX
9.5%
4.4%
TVE
Higher net margin
VRTX
VRTX
28.6% more per $
VRTX
37.3%
8.7%
TVE
More free cash flow
VRTX
VRTX
$1.2B more FCF
VRTX
$348.6M
$-814.0M
TVE
Faster 2-yr revenue CAGR
VRTX
VRTX
Annualised
VRTX
8.9%
-1.7%
TVE

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
TVE
TVE
VRTX
VRTX
Revenue
$3.0B
$3.2B
Net Profit
$266.0M
$1.2B
Gross Margin
85.4%
Operating Margin
18.1%
37.8%
Net Margin
8.7%
37.3%
Revenue YoY
4.4%
9.5%
Net Profit YoY
112.8%
30.5%
EPS (diluted)
$4.64

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
TVE
TVE
VRTX
VRTX
Q4 25
$3.0B
$3.2B
Q3 25
$3.9B
$3.1B
Q2 25
$3.3B
$3.0B
Q1 25
$3.5B
$2.8B
Q4 24
$2.9B
$2.9B
Q3 24
$3.5B
$2.8B
Q2 24
$2.9B
$2.6B
Q1 24
$3.2B
$2.7B
Net Profit
TVE
TVE
VRTX
VRTX
Q4 25
$266.0M
$1.2B
Q3 25
$615.0M
$1.1B
Q2 25
$212.0M
$1.0B
Q1 25
$408.0M
$646.3M
Q4 24
$125.0M
$913.0M
Q3 24
$520.0M
$1.0B
Q2 24
$181.0M
$-3.6B
Q1 24
$307.0M
$1.1B
Gross Margin
TVE
TVE
VRTX
VRTX
Q4 25
85.4%
Q3 25
86.5%
Q2 25
86.3%
Q1 25
86.9%
Q4 24
85.5%
Q3 24
85.8%
Q2 24
85.9%
Q1 24
87.3%
Operating Margin
TVE
TVE
VRTX
VRTX
Q4 25
18.1%
37.8%
Q3 25
23.6%
38.6%
Q2 25
15.6%
38.8%
Q1 25
20.3%
22.7%
Q4 24
14.1%
35.2%
Q3 24
22.7%
40.3%
Q2 24
15.9%
-132.9%
Q1 24
18.4%
42.4%
Net Margin
TVE
TVE
VRTX
VRTX
Q4 25
8.7%
37.3%
Q3 25
15.7%
35.2%
Q2 25
6.4%
34.8%
Q1 25
11.6%
23.3%
Q4 24
4.3%
31.4%
Q3 24
14.8%
37.7%
Q2 24
6.3%
-135.8%
Q1 24
9.7%
40.9%
EPS (diluted)
TVE
TVE
VRTX
VRTX
Q4 25
$4.64
Q3 25
$4.20
Q2 25
$3.99
Q1 25
$2.49
Q4 24
$3.62
Q3 24
$4.01
Q2 24
$-13.92
Q1 24
$4.21

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
TVE
TVE
VRTX
VRTX
Cash + ST InvestmentsLiquidity on hand
$501.0M
$6.6B
Total DebtLower is stronger
Stockholders' EquityBook value
$18.7B
Total Assets
$59.5B
$25.6B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
TVE
TVE
VRTX
VRTX
Q4 25
$501.0M
$6.6B
Q3 25
$1.6B
$6.3B
Q2 25
$501.0M
$6.4B
Q1 25
$502.0M
$6.2B
Q4 24
$507.0M
$6.1B
Q3 24
$502.0M
$6.5B
Q2 24
$501.0M
$5.8B
Q1 24
$508.0M
$10.2B
Total Debt
TVE
TVE
VRTX
VRTX
Q4 25
Q3 25
$22.1B
Q2 25
Q1 25
Q4 24
Q3 24
$19.1B
Q2 24
Q1 24
Stockholders' Equity
TVE
TVE
VRTX
VRTX
Q4 25
$18.7B
Q3 25
$17.3B
Q2 25
$17.2B
Q1 25
$16.5B
Q4 24
$16.4B
Q3 24
$15.6B
Q2 24
$14.8B
Q1 24
$18.5B
Total Assets
TVE
TVE
VRTX
VRTX
Q4 25
$59.5B
$25.6B
Q3 25
$60.9B
$24.9B
Q2 25
$59.9B
$24.0B
Q1 25
$59.3B
$22.9B
Q4 24
$58.4B
$22.5B
Q3 24
$57.7B
$22.2B
Q2 24
$56.2B
$20.1B
Q1 24
$52.3B
$23.9B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
TVE
TVE
VRTX
VRTX
Operating Cash FlowLast quarter
$330.0M
$498.0M
Free Cash FlowOCF − Capex
$-814.0M
$348.6M
FCF MarginFCF / Revenue
-26.7%
10.9%
Capex IntensityCapex / Revenue
37.5%
4.7%
Cash ConversionOCF / Net Profit
1.24×
0.42×
TTM Free Cash FlowTrailing 4 quarters
$-1.2B
$3.2B

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
TVE
TVE
VRTX
VRTX
Q4 25
$330.0M
$498.0M
Q3 25
$1.2B
$1.2B
Q2 25
$615.0M
$1.1B
Q1 25
$1.0B
$818.9M
Q4 24
$450.0M
$584.6M
Q3 24
$1.1B
$1.4B
Q2 24
$508.0M
$-3.8B
Q1 24
$1.0B
$1.3B
Free Cash Flow
TVE
TVE
VRTX
VRTX
Q4 25
$-814.0M
$348.6M
Q3 25
$233.0M
$1.1B
Q2 25
$-431.0M
$927.4M
Q1 25
$-176.0M
$778.2M
Q4 24
$-759.0M
$492.0M
Q3 24
$164.0M
$1.3B
Q2 24
$-248.0M
$-3.8B
Q1 24
$276.0M
$1.2B
FCF Margin
TVE
TVE
VRTX
VRTX
Q4 25
-26.7%
10.9%
Q3 25
6.0%
37.0%
Q2 25
-13.0%
31.3%
Q1 25
-5.0%
28.1%
Q4 24
-26.0%
16.9%
Q3 24
4.7%
47.0%
Q2 24
-8.6%
-144.5%
Q1 24
8.8%
46.0%
Capex Intensity
TVE
TVE
VRTX
VRTX
Q4 25
37.5%
4.7%
Q3 25
25.9%
3.3%
Q2 25
31.6%
4.9%
Q1 25
33.6%
1.5%
Q4 24
41.4%
3.2%
Q3 24
25.6%
2.4%
Q2 24
26.3%
2.6%
Q1 24
24.2%
2.5%
Cash Conversion
TVE
TVE
VRTX
VRTX
Q4 25
1.24×
0.42×
Q3 25
2.03×
1.15×
Q2 25
2.90×
1.04×
Q1 25
2.48×
1.27×
Q4 24
3.60×
0.64×
Q3 24
2.05×
1.31×
Q2 24
2.81×
Q1 24
3.38×
1.19×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

TVE
TVE

TN$2.0B65%
AL$449.0M15%
MS$266.0M9%
KY$193.0M6%
GA$75.0M2%
Federal Agencies And Other$29.0M1%
NC$23.0M1%
VA$12.0M0%
Off System Sales Member$2.0M0%

VRTX
VRTX

TRIKAFTAKAFTRIO$2.6B81%
ALYFTREK$380.1M12%
Manufactured Product Other$237.4M7%

Related Comparisons